Endotronix Initiates PROACTIVE-HF-2 Trial for Cordella System in Heart Failure Patients
The PROACTIVE-HF-2 trial is evaluating the safety and efficacy of the Cordella Pulmonary Artery Sensor System in patients with NYHA Class II and III heart failure.
Phase III
Cardiology / Heart Failure
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the PROACTIVE-HF-2 trial by Endotronix represents a significant step in the evaluation of innovative technologies for heart failure management. Positive trial outcomes could enhance Endotronix's competitive position and potentially reshape treatment protocols in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any announcements regarding interim findings or regulatory submissions related to the Cordella system.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.